A NEW IMMUNORADIOMETRIC ASSAY (IRMA) SYSTEM FOR THYROGLOBULIN MEASUREMENT IN THE FOLLOW-UP OF THYROID-CANCER PATIENTS

被引：48

作者：

SCHLUMBERGER, M

FRAGU, P

GARDET, P

LUMBROSO, J

VIOLOT, D

PARMENTIER, C

机构：

[1] Médicine Nucléaire, INSERM U66, Institut Gustave-Roussy, Villejuif Cedex

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1991年 / 18卷 / 03期

关键词：

THYROGLOBULIN ASSAY; THYROID CARCINOMA;

D O I：

10.1007/BF02262724

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A new commercially available kit for thyroglobulin (Tg) measurement [immunoradiometric assay (IRMA) system based on monoclonal antibodies] was used in 479 patients with thyroid carcinoma. The effective working range was 1 ng/ml, and results were strongly correlated with our homemade radioimmunoassay (RIA). This IRMA method is less susceptible to interferences of auto-antibodies than our RIA. During thyroxine (T4) treatment, the Tg level was undetectable in 98% of patients after total thyroid ablation, in 91% after total thyroidectomy and in 42% after lobectomy only. In this situation, Tg was found in all patients with large metastases and in 88% of those with small metastases. Following T4 withdrawal, Tg was detectable in all patients with neoplastic disease and in 13% of those in complete remission after total thyroid ablation. In conclusion, Tg measured with this IRMA method appears to be a reliable marker of differentiated thyroid carcinoma.

引用

页码：153 / 157

页数：5

共 17 条

[11]

SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960

[12]

SCHLUMBERGER M, 1988, J NUCL MED, V29, P1790

[13] THYROGLOBULIN ASSAY IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CARCINOMAS - COMPARISON OF ITS VALUE IN PATIENTS WITH OR WITHOUT NORMAL RESIDUAL TISSUE [J].